Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.20

Shares of Altimmune, Inc. (NASDAQ:ALT) have received an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.20.

Several research analysts have recently issued reports on ALT shares. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, April 3rd.

Insider Activity at Altimmune

In related news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction that occurred on Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 4.10% of the stock is owned by company insiders.

Institutional Trading of Altimmune

Institutional investors and hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new stake in shares of Altimmune in the fourth quarter valued at approximately $45,000. GAMMA Investing LLC increased its position in shares of Altimmune by 214.2% in the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock valued at $34,000 after buying an additional 4,598 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of Altimmune in the fourth quarter valued at approximately $60,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Altimmune in the fourth quarter valued at approximately $72,000. Finally, Magnus Financial Group LLC purchased a new stake in shares of Altimmune during the first quarter worth approximately $50,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $5.70 on Monday. The company has a market cap of $438.98 million, a PE ratio of -3.68 and a beta of 1.13. The business has a 50-day simple moving average of $5.10 and a two-hundred day simple moving average of $6.58. Altimmune has a fifty-two week low of $3.55 and a fifty-two week high of $11.16.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.09. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter last year, the company earned ($0.34) earnings per share. On average, sell-side analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.